Oak Hill Bio

UK - CheshireBiotechnology1 H-1B visas (FY2023)

Focus: Oak Hill Bio is a UK-based biotechnology company focused on small molecule therapeutics for protein misfolding diseases, currently in early-stage clinical development. The company is publicly listed with a pipeline spanning rare genetic and neonatal disorders.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Oak Hill Bio

AI assessmentNot Hiring

No open roles listed right now. Follow Oak Hill Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

No Intervention

Retinopathy of Prematurity (ROP)

N/A

Clinical Trials (1)

NCT04506619Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

N/A

Help build intelligence for Oak Hill Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Specialized focus on protein misfolding—a high-value, less-crowded therapeutic area with significant unmet need in rare diseases
Public company status provides equity upside potential and operational stability versus pre-revenue biotech
Diverse pipeline across orphan/rare indications (Angelman Syndrome, ROP, BPD) creates multiple clinical validation opportunities

Watch Out For

Currently zero active job openings signals minimal near-term hiring or potential organizational contraction
Early-stage pipeline with only one Phase 2 program—significant clinical risk and limited near-term revenue visibility
Limited public data on financials, employee count, and founding date creates opacity on company scale and stability

Generated by Claude from Oak Hill Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Rugonersen

Angelman Syndrome

N/A

Clinical Trials (1)

NCT07136454Expanded Access/Compassionate Use of Rugonersen in Patients With Angelman Syndrome

N/A

OHB-607

Bronchopulmonary Dysplasia

Phase 2

Clinical Trials (1)

NCT03253263A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Respiratory, Rare Diseases

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Respiratory

2 pipeline

Rare Diseases

1 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub